Thanks to life-saving clinical trials, selinexor (Xpovio) was able to be approved by the FDA. The drug helps with multiple myeloma and was discovered by Dan Vogl, MD, MSCE, an associate professor of Hematology-Oncology in the Perelman School of Medicine. Selinexor works by blocking the protein that transports the tumor suppressants out of the nucleus. Advancements like these wouldn’t be possible without life-changing clinical trials, which Philly Fights Cancer helps to fund through year-round fundraising and awareness building. To donate or learn more about supporting Philly Fights Cancer: Round 5, follow the link here: https://phillyfightscancer.org/events/philly-fights-cancer-round-5/. To read about the full story, visit Penn Medicine at:  https://www.pennmedicine.org/news/news-blog/2019/july/a-new-cancer-drug-thanks-to-a-new-approach.